COX Nicox SA

Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights AS OF OCTOBER 31, 2022

Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights AS OF OCTOBER 31, 2022

Nicox SA

Société anonyme with a registered capital of € 43,251,132

Head Office:

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis 

R.C.S. GRASSE 403.942.642

On November 2, 2022,

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)

 As of October 31, 2022
Total number of shares composing the share capital43,251,132
Total number of voting rights43,251,132
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights43,251,132

---------------



Phone: 00

Fax : 99

 

Attachment



EN
02/11/2022

Underlying

COXNicox SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces up to €3 million in Milestone Payments from Kowa in 20...

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in JapanMilestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025Extends Nicox’s cash runway until the end of 2025 May 27, 202...

May 27, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la p...

Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon Communiqué de presseNicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon Kowa, le partenaire exclusif de Nicox au Japon, a obtenu l’autorisation règlementaire de lancer des essais cliniques de Phase 3 sur NCX 470 pour le traitement de l’hypertension oculaire au Japon  Des paiements d’étapes pouvant atteindre ...

May 27, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma ...

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial  Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogsEpiscleral venous pressure changes did not show a trend vs. placeboSafety profile is consistent with that of the first Phase 3 trial, Mont BlancNCX 470 intraocular pressure lowering efficacy and safety have already been demonstrated in the Phase 3 glauco...

May 14, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistl...

Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome Communiqué de presseNicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome Plusieurs paramètres de l’humeur aqueuse stimulés par l’oxyde nitrique ont été statistiquement significatifs ou ont montré une tendance favorable au NCX 470 ; tout comme ceux stimulés par les analogues des prostaglandines.Les variations de la pression veineuse épisclérale n’ont pas montré de tendance notable par rapport au placeboProfil de tolérance conforme à celui observé dans la première ét...

May 14, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Provides Full Year 2024 Financial Results

Nicox Provides Full Year 2024 Financial Results Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus CapitalNicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is currently financed into the fourth quarter of 2025 Topline results from NCX 470 second Phase 3 clinical trial, Denali, expected in the third quarter of 2025Ongoing discussions and business development outreach underway for NCX 470 U.S. part...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch